AIP
RPRX icon

ARS Investment Partners’s Royalty Pharma RPRX Stock Holding History

ARS Investment Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-270,906
Closed -$13.6M – 146
2020
Q4 		$13.6M Sell
270,906
-676
-0.2% -$28.7K 1.67% 18
2020
Q3 		$11.4M Buy
271,582
+198,626
+272% +$8.52M 1.8% 16
2020
Q2 		$3.54M Buy
+72,956
New +$3.61M 0.67% 38

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ARS Investment Partners's RPRX Position: Q1 2021 in Review

ARS Investment Partners sold out of Royalty Pharma (RPRX) in Q1 2021, closing a stake of 270,906 shares — an estimated $13.6M sold.

ARS Investment Partners first reported a position in RPRX in Q2 2020 and held it in 3 quarters. The position peaked at $13.6M in Q4 2020. 213 funds tracked by Wall St. Rank hold RPRX as of Q1 2021.

  • ARS Investment Partners reported no remaining Royalty Pharma position as of Q1 2021 after selling out during the quarter.
  • ARS Investment Partners sold 270,906 Royalty Pharma shares in Q1 2021, an estimated $13.6M.
  • ARS Investment Partners first reported a position in Royalty Pharma in Q2 2020 and held it in 3 quarters.
  • ARS Investment Partners's Royalty Pharma position peaked at $13.6M in Q4 2020.
  • 213 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2021.

Based on ARS Investment Partners's 13F filing for Q1 2021, filed 13 May 2021.